Edition:
United States

Halozyme Therapeutics Inc (HALO.O)

HALO.O on Nasdaq

11.81USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$11.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,503,327
52-wk High
$18.39
52-wk Low
$6.96

Latest Key Developments (Source: Significant Developments)

Halozyme reports second quarter 2016 financial results
Tuesday, 9 Aug 2016 04:05pm EDT 

Halozyme Therapeutics Inc : Halozyme reports second quarter 2016 financial results . Q2 revenue $33.3 million versus I/B/E/S view $29.9 million . Sees FY 2016 revenue $140 million to $150 million . Q2 loss per share $0.21 . Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Sees 2016 operating expenses to continue to be in range of $245 million to $260 million .FY2016 revenue view $138.7 million -- Thomson Reuters I/B/E/S.  Full Article

Halozyme to resume enrollment in Phase 1B trial evaluating PEGPH20
Monday, 25 Jul 2016 09:00am EDT 

Halozyme Therapeutics Inc : Resumed enrollment, dosing patients in phase 1B trial evaluating investigational new drug, PEGPH20, in combination with KEYTRUDA . Revised protocol has been submitted to all institutional review boards (IRB) and is pending feedback from FDA .Majority of institutional review boards have completed their review and approved revised protocol allowing study to resume.  Full Article

Halozyme announces agreement to refinance debt
Wednesday, 8 Jun 2016 09:00am EDT 

Halozyme Therapeutics Inc : Entered into agreement with Oxford Finance Llc and Silicon Valley Bank to refinance its existing senior secured loan facility . Under new financing agreement, Halozyme borrowed $55 million at a fixed rate of 8.25% . New debt facility provides option to borrow additional $15 million in 2017 . Interest-Only repayment provision results in $44 million increase to expected cash balance through 2017 . Under new financing agreement, Halozyme used proceeds to refinance its existing long-term debt . Agreement will result in a $22 million per-year increase to company's expected cash balance at end of 2016 and 2017 . Expecting a year-end cash balance of $170 million to $190 million .Announces agreement to refinance debt, increases 2016 guidance for year-end cash balance.  Full Article

Halozyme Q1 loss per share $0.16
Monday, 9 May 2016 04:22pm EDT 

Halozyme Therapeutics Inc : Halozyme therapeutics inc sees 2016 net revenues to be in range of $130 million to $145 million . Halozyme therapeutics inc sees 2016 cash flow to be in range of $45 million to $65 million . Fy2016 earnings per share view $-0.98, revenue view $127.9 million -- Thomson Reuters I/B/E/S . Halozyme reports first quarter 2016 financial results . Q1 loss per share $0.16 . Q1 revenue $42.5 million versus $18.7 million . Q1 revenue view $29.7 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc maintains FY 2016 net revenues guidance
Monday, 29 Feb 2016 04:06pm EST 

Halozyme Therapeutics Inc:For Fy 2016, the company maintains its previously announced guidance of Net revenues to be in the range of $110 million to $125 million.  Full Article

Halozyme says closing Of $150 Million Royalty-Backed Debt Financing
Tuesday, 26 Jan 2016 04:06pm EST 

Halozyme Therapeutics Inc:Closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management.Debt is secured by future royalties of ENHANZE(tm) products, received only from Halozyme's collaborations with Roche and Baxalta.  Full Article

Halozyme enters into global collaboration and licensing agreement with Lilly
Monday, 21 Dec 2015 08:30am EST 

Halozyme Therapeutics Inc:Announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform.Under the terms of the agreement, Halozyme will receive an initial $25 million payment, followed by milestone payments of up to $160 million for each of up to five collaboration targets valued at up to $800 million.In addition, Lilly will pay Halozyme mid-single digit royalties if products under the collaboration are commercialized.  Full Article

Halozyme Therapeutics Inc reaffirms FY 2015 net revenues guidance
Monday, 9 Nov 2015 04:05pm EST 

Halozyme Therapeutics Inc:Sees FY 2015 net revenues to be in the range of $110 million to $115 million.FY 2015 revenue of $111 million - Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc raises FY 2015 revenue outlook
Monday, 10 Aug 2015 04:05pm EDT 

Halozyme Therapeutics Inc:Revises FY 2015 net revenue to be in the range of $110 to $115 million, from a prior range of $85 to $95 million.FY 2015 revenue of $96 million - Thomson Reuters I/B/E/S.  Full Article

Halozyme Therapeutics Inc plans for CFO transition, names Laurie Stelzer CFO
Friday, 5 Jun 2015 09:00am EDT 

Halozyme Therapeutics Inc:Announces plans for CFO transition, names laurie stelzer CFO.Says chief financial officer david ramsay will retire this summer.Says stelzer will assume CFO duties on June 15 and will work with ramsay through transition period.  Full Article

BRIEF-Halozyme reports Q3 loss per share $0.23

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S